...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: This caught my eye!

Going from memory, this is the first time that I have seen "prevent and reverse resistance" used. They even underlined "prevent" in the presentation!

If they use ZEN-3694 earlier in the treatment, it could become a real cash cow for us!

 

From slide 3:

Our Approach: Making Great Drugs Work Better & Longer

Combinations with ZEN-3694 to prevent and reverse resistance to standard of care therapies

Current possibilities include:

•Androgen receptor signaling inhibitors (ARSIs)
•PARP inhibitors
•PD-1/PD-L1 monoclonal antibodies (checkpoint inhibitors)
•CDK4/6
inhibitors

 

 

 

 

https://www.zenithepigenetics.com/upload/media_element/122/01/zenith-epigenetic-therapeutic-targets-2020-final.pdf

Share
New Message
Please login to post a reply